← Back to Search

MRT Accuracy for Prostate Cancer (MRI-PREDICT Trial)

N/A

Waitlist Available

Led By Dr. Michael Kucharczyk

Research Sponsored by Nova Scotia Health Authority

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Timeline

Screening 3 weeks

Treatment Varies

Follow Up at study completion, 2 years.

Awards & highlights

MRI-PREDICT Trial Summary

This trial will help doctors make better decisions about how to treat an individual patient's prostate cancer by using a computer program to predict how aggressive the cancer is.

Eligible Conditions

Prostate Cancer

MRI-PREDICT Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ at study completion, 2 years.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~at study completion, 2 years.

This trial's timeline: 3 weeks for screening, Varies for treatment, and at study completion, 2 years. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

MRT Classification Change

MRT Classification: Baseline

MRT Classification: Week 8

Secondary outcome measures

Model optmization with novel radiomic features and clinical covariates

MRI-PREDICT Trial Design

1Treatment groups

Experimental Treatment

Group I: Prospective CohortExperimental Treatment2 Interventions

Sixty patients with a new diagnosis of prostate cancer that meet eligibility criteria. The group will have two standard MRI-P's completed. The first MRI-P will be acquired as standard of care and the second will be an additional investigation for the purposes of this study. The efficacy of the MRT will be compared at both time points, evaluating if the MRT demonstrates clinically sufficient stability in its findings (i.e., does the MRT report an accurate and similar result at both time points).

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Nova Scotia Health AuthorityLead Sponsor

257 Previous Clinical Trials

83,754 Total Patients Enrolled

4 Trials studying Prostate Cancer

798 Patients Enrolled for Prostate Cancer

Dr. Michael KucharczykPrincipal InvestigatorNova Scotia Health Authority

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many individuals are participating in this clinical experiment?

"Affirmative. Information from clinicaltrials.gov indicates that this medical investigation, which was made available on 4th of January 2022, is actively seeking participants. Approximatively 60 individuals require recruitment for trials at a single centre."

Answered by AI

Are there still opportunities to join this experiment?

"Affirmative. According to clinicaltrials.gov, this research project has commenced recruiting and was originally posted on April 1st 2022 with the most recent update occurring on March 7th 2022. 60 participants are being enrolled from one site of engagement."

Answered by AI

Recent research and studies

CancersJournal

Multimodal Radiomic Features for the Predicting Gleason Score of Prostate Cancer

Chaddad, Ahmad, Michael Kucharczyk, and Tamim Niazi. 2018. “Multimodal Radiomic Features for the Predicting Gleason Score of Prostate Cancer”. Cancers. MDPI AG. doi:10.3390/cancers10080249.

British Journal of Mathematical and Statistical PsychologyJournal

Computing Inter-rater Reliability and Its Variance in the Presence of High Agreement

Gwet, Kilem Li. 2008. “Computing Inter-rater Reliability and Its Variance in the Presence of High Agreement”. British Journal of Mathematical and Statistical Psychology. Wiley. doi:10.1348/000711006x126600.

Frontiers in OncologyJournal

Repeatability of Quantitative Imaging Features in Prostate Magnetic Resonance Imaging

Lu, Hong, Nestor A. Parra, Jin Qi, Kenneth Gage, Qian Li, Shuxuan Fan, Sebastian Feuerlein, et al.. 2020. “Repeatability of Quantitative Imaging Features in Prostate Magnetic Resonance Imaging”. Frontiers in Oncology. Frontiers Media SA. doi:10.3389/fonc.2020.00551.

CancersJournal